Cystic Fibrosis

CTAF

Due to the COVID-19 pandemic, we have decided to postpone our upcoming public meeting on modulator therapies for cystic fibrosis to August 27, 2020


Cystic fibrosis is an autosomal recessive condition caused by mutations in the CFTR gene. It is relatively rare, occurring in approximately 1 in 2,500 to 3,000 livebirths, but is the most common, lethal genetic disease in Caucasian populations. CF is a progressive disease that affects many organ systems, but most of its morbidity and mortality are associated with its impact on the respiratory system.

Interventions of Interest:

    • Tezacaftor/ivacaftor (SymdekoTM, Vertex Pharmaceuticals)
    • Lumacaftor/ivacaftor (Orkambi®, Vertex Pharmaceuticals)
    • Ivacaftor (Kalydeco®, Vertex Pharmaceuticals)
    • Elexacaftor/tezacaftor/ivacaftor (Vertex Pharmaceuticals)

Date of review: August 2020 (originally April 2020, but was postponed due to COVID-19) 

Click here to see ICER’s 2018 cystic fibrosis review

For questions, please contact Matt Seidner, Program Director, at mseidner@icer-review.org.

ASSOCIATED MEETING & MATERIALS

CTAF
August 27, 2020 9 am - 2 pm PT

Virtual

Due to the COVID-19 pandemic, we have decideded to postpone our upcoming public meeting on modulator therapies for CF (originally slated for April 30) to August 27, 2020. The CTAF will convene virtually to deliberate and vote on evidence presented in ICER's report on therapies for cystic fibrosis.

Key Dates

Associated Materials

09/06/2019 – 09/25/2019
Open Input Period

09/30/2019

09/30/2019 – 10/21/2019

09/30/2019

10/29/2019

12/05/2019

12/16/2019

02/20/2020

02/20/2020

02/20/2020 – 03/25/2020

04/27/2020

04/27/2020

04/27/2020

08/27/2020

08/27/2020
Evidence Presentation

09/23/2020
Final Evidence Report and Meeting Summary

09/23/2020
Report-at-a-Glance

09/23/2020
Final Policy Recommendations


ASSOCIATED MEETING & MATERIALS

Midwest CEPAC
May 17, 2018 9:30am-3:30pm CT

ICER’s first CF review
University of Missouri-St. Louis
Century BC Room, Millennium Student Center
1 University Boulevard
St. Louis, MO 63121

The Midwest CEPAC will convene to discuss treatments for cystic fibrosis.

Key Dates

Associated Materials

10/11/2017 – 10/27/2017

10/31/2017

10/31/2017

10/31/2017 – 11/20/2017

11/30/2017

02/07/2018

02/07/2018

03/15/2018

Open to public comment from March 15 – April 12, 2018. For more information on submitting a public comment, please visit our stakeholder engagement page.